Spruce Biosciences Posts $24M Q3 Loss, Cash of $87.7M Ahead of December BLA Filing
SPRB sits 22% above its 52-week low of $38.06.
Summary
Spruce reported a Q3 2026 net loss of $24.0 million, or $(8.51) per share, versus $8.2 million a year ago, as R&D spending jumped to $18.1 million from $5.0 million on TA-ERT manufacturing and clinical work. Cash stood at $87.7 million as of September 30, which management says funds operations and debt obligations into the second half of 2027. The company reaffirmed its BLA submission for TA-ERT in MPS IIIB for December 2026, with the second PPQ batch and the TrAnsform confirmatory study also slated to start that month. On the financing side, an amended Avenue loan agreement raises Tranche 2 availability to up to $15.0 million and extends the interest-only period through March 31, 2027. The CRHX-101 program now sits in Adrenyx Biosciences, which issued $5.0 million of a planned $10.0 million convertible note at its initial closing; the planned pro rata distribution to Spruce holders is targeted for the first half of 2027, pending board approval and a Nasdaq listing.
At the time of this announcement, SPRB was trading at $46.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $38.06 to $129.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.